---
layout: default
title: Degarelix
parent: 僅模型預測 (L5)
nav_order: 45
evidence_level: L5
indication_count: 10
---

# Degarelix
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

The `txgnn-pipeline` skill covers pipeline operations; this task is report generation as defined by the system prompt. Proceeding directly with the report.

---

# Degarelix: Evaluation Incomplete — No TxGNN Predictions Available

## One-Sentence Summary

Degarelix (DrugBank: DB06699) is a drug with confirmed DrugBank records, but the current evidence pack contains neither a confirmed original indication nor a confirmed mechanism of action.
The TxGNN model returned **no predicted new indications** for this candidate, making a standard repurposing evaluation impossible at this stage.
Critical data gaps — including MOA, safety warnings, and indication mapping — must be resolved before any evidence-based assessment can be conducted.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in current data |
| Predicted New Indication | None returned by TxGNN |
| TxGNN Prediction Score | — |
| Evidence Level | L5 (no supporting studies; model returned no output) |
| Taiwan Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline returned an empty prediction list for Degarelix, which means there is no repurposing target to evaluate. Combined with absent MOA data and zero Taiwan regulatory records, the minimum conditions for a meaningful assessment are not met.

**To proceed, the following is needed:**

- **Resolve MOA gap (High priority):** Query DrugBank API (DB06699) to retrieve the mechanism of action and pharmacological class — this is required for both indication matching and cytotoxicity classification
- **Resolve safety gap (Blocking):** Download and parse the TFDA package insert PDF (confirmed available per `query_log` entry #4) to extract key warnings and contraindications
- **Investigate TxGNN empty output:** Verify that Degarelix is correctly mapped in the knowledge graph's disease–gene–drug network; an empty prediction list often indicates a missing node or broken entity linkage in the KG
- **Confirm original indication:** Cross-reference EMA / FDA / DrugBank indication field to establish the ground-truth approved use before re-running the prediction pipeline
- **Re-run prediction pipeline** after the above steps are completed and re-submit an updated evidence pack
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

